- Home
- BGY vs CATX Comparison
BGY vs CATX Comparison
Compare BGY & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGY | CATX |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.6M | 497.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BGY | CATX |
|---|---|---|
| Price | $5.76 | $3.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 316.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $1.96 |
| 52 Week High | $6.23 | $6.16 |
Technical Indicators
Market Signals| Indicator | BGY | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 37.11 |
| Support Level | $5.68 | $3.24 |
| Resistance Level | $5.87 | $4.74 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 46.30 | 11.36 |
Price Performance
Historical ComparisonAbout BGY Blackrock Enhanced International Dividend Trust
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.